$7.64-4.9%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 5, 2026
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $9.2M | $29.7M | -69.19% |
| Profit | -$40.7M | -$61.9M | +34.23% |
| Profit per share | -$0.62 | -$1.20 | +48.33% |
| Free Cash Flow | $38.4M | -$56.5M | +168.05% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“We are continuing to build momentum as we prepare to launch potential first- or best-in-class gene therapies in 2027 and 2028,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
The quote and the company description come from Regenxbio Inc.’s Item 2.02 8-K filed November 5, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Regenxbio Inc. reported on November 5, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
Just reported
From Regenxbio Inc.'s results release of November 5, 2026; its quarterly report has since been filed.
Actual
$9.2M
-69% y/y
-92% q/q
Guided
—
No guide given
Actual
-$0.62
Guided
—
No guide given
Actual
-$35.5M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.